Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up.

Solal-Celigny, P.; Imrie, K; Belch, A; Robinson, KS; Cunningham, D.; Rueda, A; Catalano, J; Offner, F.; Walewski, J; Raposo, J; Smith, P.; Marcus, R

Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up.

Solal-Celigny, P.

;

Imrie, K

;

Belch, A

;

Robinson, KS

;

Marcus, R

;et.al.

(2005) 47th Annual Meeting of the American-Society-of-Hematology — Location: Atlanta(Ga) (10.December.2005)

Files

No attached file found for this publication.

Details

Authors

Solal-Celigny, P.
Author
Imrie, K
Author
Belch, A
Author
Robinson, KS
Author
Marcus, R
Author

Affiliations

UCLouvainAutre

Citations

APA
Chicago
FWB

Solal-Celigny, P., Imrie, K., Belch, A., Robinson, K., Cunningham, D., Rueda, A., Catalano, J., Offner, F., Walewski, J., Raposo, J., Smith, P., & Marcus, R. (2005). Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma (NHL): Confirmed efficacy with longer follow-up. Blood, 106(11), 106A. https://hdl.handle.net/2078.5/140221 (Original work published 2005)